Caliway Biopharmaceuticals Co. L
6919
Rangering i aksjer
#4346
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated... Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phase 2 clinical trials, targeting non-surgical fat reduction, Dercum's disease, and cellulite. Beyond this, the firm is also progressing CBA-539 through preclinical exploration for potential applications in central obesity, hyperpigmentation, and skin aging. The company's offerings also extend to dietary supplements. Established in 2012, Caliway Biopharmaceuticals operates from its headquarters in New Taipei City, Taiwan.
Aksjekurs
$2.29
Markedsverdi
$3.56B
Endring (1 dag)
-2.50%
Endring (1 år)
-57.22%
Land
TW
Handel Caliway Biopharmaceuticals Co. L (6919)
Kategori
Healthcare
P/S-forhold for Caliway Biopharmaceuticals Co. L (6919)
P/S-forhold per 2026 TTM: 0
Ifølge Caliway Biopharmaceuticals Co. L sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for Caliway Biopharmaceuticals Co. L fra 2026 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| Ikke nok data for de angitte datoene. | ||
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| 10.15 | - |
NL
|
|
| - | - |
CH
|
